Functional Recovery Effect of Bloodletting Puncture at Jing-well Points on Acute Brain Injury Patients
To Evaluate the Functional Recovery Effect of Bloodletting Puncture at Jing-well Points on Acute Brain Injury Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: wei Ling Chou
- Phone Number: +886 975360906
- Email: wenni1207@cgmh.org.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Chang Gung Memorial Hospital
-
Contact:
- Wei Ling Chou
- Phone Number: +886 975360906
-
Principal Investigator:
- Wei Ling Chou
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with moderate to severe head injury are admitted to the ICU (Intensive Care Unit). patient with stable vital sign and the GCS (Glasgow coma volume) between 5-13 will be included.
- Patient with normal consciousness and no cognitive or motor function disease before brain injury.
- Patient aged between 20 to 80 years old and is willing to sign the consent (the agent can sign on behalf of patient).
Exclusion Criteria:
- Patients who are vital sign unstable and with severe complication.
- Patients combined with other terminal illness such as cancer in terminal stage, liver failure, end stage renal failure and so on.
- Pregnant patients.
- Any other conditions deemed unsuitable by the physician in charge.
- Patients (agent of the patient) who did not sign the consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention group (Severe)
A patient's Glasgow Coma Score (GCS) between 5-8
|
bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
|
|
NO_INTERVENTION: Control group (Severe)
A patient's Glasgow Coma Score (GCS) between 5-8
|
|
|
EXPERIMENTAL: Intervention group (Moderate)
A patient's Glasgow Coma Score (GCS) between 9-13
|
bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
|
|
NO_INTERVENTION: Control group (moderate)
A patient's Glasgow Coma Score (GCS) between 9-13
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GCS(Glasgow Coma Scale)
Time Frame: 4 weeks
|
To assess the recovery of consciousness.
Lower GCS scores are correlated with higher risk of death.
|
4 weeks
|
|
Barthel index
Time Frame: 4 weeks
|
To assess the activities of daily life.
|
4 weeks
|
|
Muscle power
Time Frame: 4 weeks
|
To assess the recovery of muscle power.
|
4 weeks
|
|
mGOS(Modified Glasgow Outcome Score)
Time Frame: 4 weeks
|
To assess the neurological outcomes, score 1 to 5. the higher the score, the better outcome.
|
4 weeks
|
|
RTS (Revised Trauma Score)
Time Frame: 4 weeks
|
To assess the physiologic condition of patients.
The Revised Trauma Score is made up of a three categories: Glasgow Coma Scale, systolic blood pressure, and respiratory rate.
The score range is 0-12.
A lower score indicates a higher severity of injury.
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Meridian energy assessment
Time Frame: 4 weeks
|
To assess meridian energy by Meridian Energy Analysis Device (M.E.A.D. )
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: wei Ling Chou, Chang Gung Medical Foundation
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202100683A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.